GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou, Zhejiang

Jia Wu, Hanzhou, Zhejiang